University of Colorado Anschutz Medical Campus: Research to Revenue

University of Colorado Anschutz Medical Campus

Summit Venture Studio

Research to Revenue Report

Summit Venture Studio (SVS) Opportunities

SVS has identified 10 commercialization opportunities from University of Colorado Anschutz Medical Campus and scored them based on our proprietary metrics and rubrics.

The SVS model is to identify the top 1% of commercialization opportunities and start companies around them.

Please connect with SVS if you would like to engage with us in our startup and investment efforts.

Return on Research (ROR) Analysis

Commercialization Revenue per Research Dollar

Top Universities by Return on Research (ROR)

ROI Ratio: Commercialization Revenue ÷ Research Funding

University Innovation Analysis

Total Innovation Scores by Institution

Top Universities by Innovation Score

180+ High Innovation

150-179 Strong Innovation

130-149 Moderate Innovation

100-129 Emerging Innovation

130+ total score considered high innovation impact

SVS Innovation Index

Proprietary Assessment of University of Colorado Anschutz Medical Campus's Innovation Ecosystem
Score out of 100. Benchmark: Top 50 U.S. research institutions.
A score of 90/100 can be read "doing better than 90% of schools benchmarked"

Innovation Visibility

73/100

Definition: Media mentions, publication count, and global research visibility metrics

Startup Momentum

8/100

Definition: Growth in patents, funding, and startup formation

Ecosystem Strength

47/100

Definition: Tech transfer infrastructure and support systems

Innovation Legacy

A Timeline of Groundbreaking Discoveries

Innovation Timeline

Founded

2007

First Nobel

1998

First Patent

1983

First IPO

N/A

2022-2024

AI-driven drug discovery

2025

Today

Notable Commercialization Outcomes

Nobel Prizes

2000

Antibody Patent

First patent for antibody technology

2000

Cancer Drug

Developed novel cancer therapy

2009

Startup Launch

Founded biotech startup company

2014

CRISPR Licensing

Exclusive CRISPR tool license

2017

COVID Vaccine

Contributed to vaccine development

2020

Competitive Benchmarking

University of Colorado Anschutz Medical Campus vs. Peer Research Universities

University of Colorado Anschutz Medical Campus vs Peers Comparison

Metric	University of Colorado Anschutz Medical Campus (FY2023)	Peer Average	Elite Average
Annual R&D Expenditure	$686M	$855M	$1,675M
New Inventions Disclosed	1	200	400
Startups Formed	4	7	10
Visibility Index	19	12	23
Licensing Revenue	$10M	$17M	$46M

Note: Peer Average = Median value among U.S. R1 research universities. Elite Average = Top 10 ranked U.S. research universities.

Emerging Opportunities

1. AI-Driven Precision Medicine Enhances Cancer Treatment Outcomes

Advanced AI algorithms personalize cancer therapies, addressing treatment resistance and improving survival rates, tapping into a $200B oncology market with scalable, data-driven solutions.

2. Novel Immunotherapies Target Autoimmune Diseases with Enhanced Efficacy

Innovative immune-modulating technologies address unmet needs in autoimmune disorders, promising scalable treatments in a $50B market with strong competitive differentiation.

3. Next-Gen Biodegradable Implants Revolutionize Orthopedic Recovery

Developing bioresorbable implants reduces complications and recovery times in orthopedic surgeries, targeting a $15B global market with high scalability and patient-centric advantages.

4. Digital Health Platforms Transform Chronic Disease Management

Integrated mobile and cloud-based solutions improve monitoring and adherence for chronic illnesses, addressing $100B healthcare inefficiencies with scalable, patient-focused technology.

5. Cutting-Edge Gene Editing Techniques Advance Rare Disease Therapies

Precise CRISPR-based platforms offer scalable cures for rare genetic disorders, addressing significant unmet medical needs in a rapidly growing biotech market.

6. Wearable Biosensors Enable Real-Time, Non-Invasive Health Monitoring

Innovative biosensor technology delivers continuous health data, tackling diagnostic delays in chronic conditions, scalable across consumer and clinical markets with competitive edge.